Status of metformin in the drug treatment for type 2 diabetes mellitus based on the update of guidelineYANG Yan, YU Xue-feng884-888
Clinical application of SGLT2 inhibitor:starting from and surpassing hypoglycemic effectZANG Li, MU Yi-ming889-893
Is a fixed drug combination of hypoglycemic agents more advantageous in the treatment of type 2 diabetes?LI Qian, MA Jian-hua894-898
Treatment for type 2 diabetes based on intestinal hormone:a new starting point beyond traditionLI Xiao-mu899-902
Exploration of precision diagnosis and treatment under DRG payment mode——the multidisciplinary diagnosis and treatment of coronary artery diseaseLIU Wei-jing, MA Chao, XU Ya-wei, LYU Zhong-wei906-910
Interpretation of the expert consensus on the treatment for renal anemia with Roxadustat in ChinaLI Zuo-lin, LIU Hong, LIU Bi-cheng911-914
Current situatioon and insights of diagnosis and treatment of thyroid cancer in real worldYIN Jia-jing, WANG Ren-fei, QU Shen915-919
Predictive value of PAR-2 for in-stent restenosis after percutaneous coronary intervention in patients with coronary artery diseaseZHOU Qian-xing, YAN Gao-liang, LIU Yao-wu, ZHU Di-di, YUAN Chun-ju, CHEN Long, MA Gen-shan920-924